BlossomHill Therapeutics, Inc. filed its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission on September 18, 2026, covering the quarterly period ended June 30, 2026.

Key Highlights

  • Share count: As of September 16, 2026, the company had 31,784,909 shares of common stock, $0.0001 par value per share, outstanding.
  • Exchange listing: Common stock trades on the Nasdaq Global Select Market under the symbol BLSM.
  • Company classification: BlossomHill Therapeutics is identified in the filing as a non-accelerated filer, smaller reporting company, and emerging growth company.
  • Pipeline candidates: The filing references three product candidates by name: BH-30643, BH-30236, and BH-501284, each under development as potential monotherapy and combination therapy regimens.
  • Filing compliance: The registrant indicated it has not filed all reports required during the preceding 12 months, checking "No" on the corresponding compliance question.

BlossomHill Therapeutics Quarterly Disclosure: Pipeline, Status, and Company Profile

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM), a Delaware-incorporated biopharmaceutical company headquartered at 10255 Science Center Drive, Suite 200, San Diego, CA 92121, submitted its Form 10-Q for the quarterly period ended June 30, 2026. The filing was made under Commission File Number 001-43435 and covers operations through the second quarter of fiscal year 2026.

According to the filing, the company's development focus centers on three named product candidates: BH-30643, BH-30236, and BH-501284. The registrant described its intentions to advance these candidates as both monotherapy and combination therapy regimens, to pursue regulatory approvals, and to evaluate them for potential additional indications. The filing notes that the company relies on third-party service providers, including suppliers and manufacturers, in conducting its research and development activities.

The filing discloses that BlossomHill Therapeutics qualifies as an emerging growth company under the JOBS Act and has not elected to use the extended transition period for complying with new or revised financial accounting standards. The registrant also confirmed it is not a shell company. The company noted it checked "No" when asked whether it had filed all required Exchange Act reports during the preceding 12 months, indicating a gap in prior period filings. All forward-looking statements in the report are the company's own and are subject to its cautionary language regarding known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially.

What Was Disclosed

BlossomHill Therapeutics filed a Form 10-Q for the period ended June 30, 2026, disclosing its share count, exchange listing, emerging growth company status, three named pipeline candidates, and a prior-period filing compliance gap.